| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 12.9 | 11.6 |
| Gross profit | 11.1 | 9.7 |
| Profit before tax | -8.8 | -10.8 |
| Net income | -8.9 | -10.8 |
| EPS (diluted, $ a share) | $-0.15 | $-0.96 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +11.3% |
|---|---|
| Gross margin | 86.2% |
| Operating margin | -59.9% |
10-Q filed with the SEC, NASDAQ: TLSI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
TriSalus Life Sciences, Inc.: key numbers
- Share price
- $2.27Close, Nov 16
- Market cap
- $140M
- Shares outstanding
- 61.7MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from TriSalus Life Sciences, Inc.
All →TriSalus Life Sciences Insider Mats Wahlstrom Buys $112K of Stock
Mats Wahlstrom bought 50,000 shares of TriSalus Life Sciences, Inc. at $2.24 a share, worth $112K in total on Nov 12, 2026. Shares held after the trade: 197,555 (+33.9%).
- Value
- $112K
- Shares
- 50,000
- Price
- $2.24
- Holding change
- +33.9%
- Trade date
- Nov 12, 2026
TriSalus Life Sciences Financial Results
TriSalus Life Sciences reported Q3 2026 revenue of $12.9 million, representing 11.3% year-over-year growth driven by increased TriNav unit sales. The company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million and highlighted recent FDA clearance for its TriNav Advance system.
“The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice.”
Mary Szela, President and Chief Executive Officer
“Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists.”
Mary Szela, President and Chief Executive Officer
TriSalus Life Sciences Regulatory Approval
TriSalus Life Sciences received FDA 510(k) clearance for its TriNav Advance device, an expansion of its Pressure-Enabled Drug Delivery (PEDD) portfolio. The device is designed to access small, distal vessels during liver embolization procedures and the company expects to commence commercialization in the coming weeks.